Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMWIDJK)

Drug Name
FORMESTANE Drug Info
Synonyms
formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; NSC 282175; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; UNII-PUB9T8T355; CCRIS 7483; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS002153359; MLS000028826; PUB9T8T355; CHEBI:75172
Cross-matching ID
PubChem CID
11273
ChEBI ID
CHEMBL132530
CAS Number
CAS 566-48-3
TTD Drug ID
D0B6PZ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Fatty acid degradation 2.32 0.00e+0 40/43 (93.02%) ADH5;ALDH3A2;ACSL5;...
Mineral absorption 2.19 0.00e+0 48/60 (80%) MT2A;MT1H;MT1G;...
Ascorbate and aldarate metabolism 2.03 0.00e+0 15/30 (50%) UGT2B28;ALDH3A2;UGT2B4;...
Histidine metabolism 1.88 8.59e-3 16/22 (72.73%) HAL;MAOB;CNDP2;...
Tyrosine metabolism 1.79 2.29e-2 30/36 (83.33%) MAOB;ADH5;AOX1;...
Steroid hormone biosynthesis 1.76 2.39e-2 43/61 (70.49%) UGT2B28;HSD11B1;UGT2B4;...
Retinol metabolism 1.74 3.19e-2 41/68 (60.29%) ADH5;AOX1;UGT2B28;...
PPAR signaling pathway 1.68 4.65e-2 66/74 (89.19%) PLIN2;FABP1;GK;...
Thermogenesis -1.71 1.48e-2 173/232 (74.57%) NDUFA1;ATP5MG;NPR1;...
Antigen processing and presentation -1.71 1.48e-2 60/78 (76.92%) TAP1;IFI30;CIITA;...
Toll-like receptor signaling pathway -1.74 1.20e-2 94/104 (90.38%) MAP2K1;MAPK13;AKT3;...
T cell receptor signaling pathway -1.74 1.24e-2 93/104 (89.42%) IL5;MAPK9;PIK3CB;...
C-type lectin receptor signaling pathway -1.74 1.29e-2 93/104 (89.42%) PTGS2;MAPKAPK2;MAPK13;...
Leishmaniasis -1.77 7.84e-3 67/77 (87.01%) FOS;HLA-DQB1;NFKB1;...
Chagas disease -1.78 8.17e-3 93/102 (91.18%) CD3G;PLCB2;NFKB1;...
Amoebiasis -1.78 8.52e-3 99/102 (97.06%) COL1A2;PLCB2;NFKB1;...
Human T-cell leukemia virus 1 infection -1.78 8.91e-3 197/219 (89.95%) IL15RA;FOS;HRAS;...
Type I diabetes mellitus -1.78 8.67e-3 38/43 (88.37%) HLA-A;IL1A;HLA-E;...
Human cytomegalovirus infection -1.82 4.20e-3 201/225 (89.33%) MAP2K1;RAC3;MAPK13;...
Mitophagy -1.86 2.21e-3 56/68 (82.35%) RAB7A;GABARAPL2;TBC1D17;...
Intestinal immune network for IgA production -1.86 2.33e-3 38/48 (79.17%) PIGR;ITGB7;HLA-DPA1;...
Diabetic cardiomyopathy -1.90 1.65e-3 162/203 (79.8%) COL1A2;NDUFB7;PLCB2;...
Asthma -1.91 1.75e-3 25/31 (80.65%) HLA-DPA1;HLA-DRB1;FCER1G;...
Non-alcoholic fatty liver disease -1.93 1.87e-3 126/155 (81.29%) NDUFB7;NFKB1;COX6A2;...
Inflammatory bowel disease -1.93 2.00e-3 58/65 (89.23%) HLA-DQB1;NFKB1;MAF;...
TNF signaling pathway -1.93 2.15e-3 103/112 (91.96%) NFKB1;CASP3;JUN;...
Allograft rejection -1.94 2.33e-3 32/38 (84.21%) HLA-F;HLA-C;HLA-DPA1;...
Tuberculosis -1.96 2.55e-3 159/180 (88.33%) MAPK13;RAB5C;PLK3;...
Phagosome -1.97 2.80e-3 118/152 (77.63%) THBS3;HLA-A;MSR1;...
Th1 and Th2 cell differentiation -1.98 3.11e-3 80/92 (86.96%) FOS;HLA-DQB1;CD3G;...
Epithelial cell signaling in Helicobacter pylori infect... -2.04 1.75e-3 62/70 (88.57%) SRC;ATP6V0B;MET;...
IL-17 signaling pathway -2.04 2.00e-3 84/94 (89.36%) IL17RA;MMP1;FOS;...
Malaria -2.06 0.00e+0 44/50 (88%) ICAM1;KLRK1;GYPC;...
Vibrio cholerae infection -2.07 0.00e+0 44/50 (88%) ATP6AP1;KDELR3;ATP6V0B;...
Oxidative phosphorylation -2.08 0.00e+0 93/133 (69.92%) ATP6V1H;NDUFA1;ATP5MG;...
Graft-versus-host disease -2.25 0.00e+0 32/42 (76.19%) HLA-A;IL1A;HLA-E;...
Rheumatoid arthritis -2.30 0.00e+0 78/93 (83.87%) MMP1;FOS;ATP6V0B;...
Staphylococcus aureus infection -2.31 0.00e+0 72/95 (75.79%) CAMP;DEFB4A;HLA-DQB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H